


## Biogen, Neurimmune announce Option Exercise for Aducanumab

02 May 2018 | News

**Transaction an increase profit potential of aducanumab for Biogen and provides near-term capital to Neurimmune**



Biogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen's Phase 3 investigational treatment for early Alzheimer's disease.

Biogen will make a one-time \$50 million payment to Neurimmune in exchange for a 5% reduction in the original royalty rates on potential commercial sales of aducanumab, which follows the 15% reduction in royalty rates announced in October 2017. The reduced royalty rates on potential commercial sales of aducanumab will be in the high single digits to low-teens.

Biogen licensed the worldwide rights to aducanumab from Neurimmune in 2007.